ArticleJournal of nanobiotechnology2025
Gut microbiome restoring biogenic ferritin mineral as an effective oral iron supplement for iron deficiency anemia.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nano-enabled strategies for iron deficiency and iron deficiency anemia: iron-based nanoparticles for supplementation, bioavailability, and food fortification-a narrative review.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
- Article
- Sustainable nanomaterials for precision dental medicine: green synthesis, therapeutic applications, and future directions.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Traditional iron supplements for iron deficiency anemia (IDA) have several limitations, including suboptimal absorption, gastrointestinal discomfort, and concerns regarding long-term safety. In this study, we synthesized monodisperse 6-line ferrihydrite as an innovative iron supplement, featuring a structure analogous to the natural "iron core" present in ferritin. Notably, 6-line ferrihydrite (6-Fh) was internalized by Caco-2 cells via a process independent of divalent metal transporter 1 (DMT1). Additionally, its stability as nanoparticles within the gastrointestinal tract prevents the irritation typically associated with metal ions, thereby significantly enhancing iron utilization efficiency. Consequently, compared to FeSO₄ (a traditional oral iron supplement), 6-Fh effectively stabilized cellular free iron with low ROS toxicity and high biosafety, thereby effectively maintaining intestinal barrier integrity and avoiding liver injury. Furthermore, it restored intestinal dysbiosis caused by IDA and increased the proportion of beneficial bacterial strains, which was superior to FeSO₄. Characterized by low toxicity, efficient cellular absorption, intestinal stability, and superior iron supplementation efficacy compared with conventional iron supplements, 6-Fh demonstrates compelling therapeutic advantages and holds great promise for medical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.